Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516265 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
EnterprisewideAdd to Basket
Electronic (PDF)Add to Basket
Live Chat Live Help Software for Website

Monoclonal Antibodies: 2010

Datamonitor, Oct 2010, Pages: 201


  Description  
   Table of Contents   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Introduction
Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines. As a result, there is a strong correlation between a strong MAbs portfolio and overall company

Features and benefits
- Strategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target.
- The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.
- The impact of biosimilars on future MAb sales growth is evaluated and compared with small molecule brand sales following genericization

Highlights
While it is believed that biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry.

Your key questions answered
- Assess the outlook for the monoclonal antibodies sector through to 2015
- Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universe
- Appraise the technological developments being made in the sector and see where monoclonal antibody pipelines are being focussed




For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds